Shares rose 7.3% to $29.40 after the Waltham, Mass.-based firm on Thursday gave an update on data from the Phase 1 study of elacestrant (RAD1901) in patients with estrogen receptor positive (ER+) breast cancer. The data presentation took place at the 2017 San Antonio Breast Cancer Symposium.
News
- Erytech Pharma Plummets on Phase 2 Data -- Biotech Movers
- Blood Test May Help Predict Which Breast Cancers Will Recur
Sparano led the study and gave results Friday at the San Antonio Breast Cancer Symposium. The test—CellSearch, sold by Menarini-Silicon Biosystems—looks for stray cancer cells in the blood. Breast cancer survivors may be tempted to rush out and get it, but doctors say it's too soon for that.…
- Arvinas Presents New Data on Oral Estrogen Receptor PROTAC Degrader at 2017 San Antonio ...
NEW HAVEN, Conn., Dec. 8, 2017 /PRNewswire/ -- Arvinas LLC, a private biotechnology company creating a new class of small molecule drugs based on protein degradation, today announced the presentation of new preclinical data for its novel oral estrogen receptor (ER) alpha PROTAC program…
- 3 Things In Biotech You Should Learn Today: December 8, 2017
News: NVS presented the findings from MONALEESA-7 at the San Antonio Breast Cancer Symposium, which explored the use of ribociclib (branded Kisqali) and endocrine therapy in premenopausal women with metastatic hormone-positive breast cancer. The findings were stellar, with a substantial…
- Trovagene Presents Data Showing Sensitivity of Triple Negative Breast Cancer (TNBC) Cell Lines ...
... biotechnology company, today announced that preclinical data demonstrating the sensitivity of triple negative breast cancer (TNBC) cell lines to PCM-075, its highly selective Polo-like kinase 1 (PLK1) Inhibitor, will be featured as a Poster Presentation at the 40th San Antonio Breast Cancer…